| Outcome Measures: |
Primary: Adverse event frequency, Number of adverse events occuring through the observational period, 14 days after completion of treatment | Secondary: Significant ASAT elevation, Number of patients with significant (\>2× ULN or \>5× baseline) serum aspartate aminotransferase elevation, continuously, 14 days after completion of treatment|Significant ALAT elevation, Number of patients with significant (\>2× ULN or \>5× baseline) serum alanin aminotransferase elevation, continuously, 14 days after completion of treatment|Significant ALP elevation, Number of patients with significant (\>2× ULN or \>5× baseline) serum alkaline phosphatase elevation, continuously, 14 days after completion of treatment|Significant seBi elevation, Number of patients with significant (\>2× ULN or \>5× baseline) serum total bilirubin elevation, continuously, 14 days after completion of treatment|Frequency of suspected drug-induced injury, Number of patients with drug induced liver injury, continuously, 14 days after completion of treatment|QTc prolongation, Change in corrected QTc interval measured on 12-lead ECG, corrected by Bazett's formule, continuously, 14 days after completion of treatment|Arrhythmia occurence, Number of patients with clinically significant (judged by investigator) ECG abnormalities, continuously, 14 days after completion of treatment
|
